Adherex Technologies Inc., of Ottawa, Ontario, was issued a U.S. patent for compounds that inhibit cancer metastasis via OB-cadherin (cadherin-11) antagonism.
Cepheid Inc., of Sunnyvale, Calif., was granted U.S. Patent No. 6,602,473, which covers aspects of the I-CORE heating system used in its Smart Cycler and GeneXpert systems for the rapid detection and assessment of genetic targets.
Cypress Bioscience Inc., of San Diego, was awarded U.S. Patent No. 6,602,911 covering methods of treating fibromyalgia syndrome with various dosages and formulations of milnacipran, a first-in-class, dual-acting reuptake inhibitor that acts on norepinephrine and serotonin, which are involved with the modulation and processing of chronic pain.
Dharmacon Inc., of Lafayette, Colo., was awarded U.S. Patent No. 6,590,093, further protecting processes and compounds related to its 2'-ACE chemistry, Dharmacon's core technology for the production of synthetic RNA oligonucleotides.
Diversa Corp., of San Diego, was issued U.S. Patent No. 6,602,675, which is directed to small-molecule and enzyme discovery from both cultured and uncultured filamentous fungi and bacteria using high-throughput fluorescent screening.
Genaera Corp., of Plymouth Meeting, Pa., was awarded U.S. Patent No. 6,602,850 covering the use of certain soluble human interleukin-9 receptor protein variants as a method for treating bronchial hyperresponsiveness and asthma.
Isotechnika Inc., of Edmonton, Alberta, received U.S. Patent No. 6,605,593 titled "Deuterated Cyclosporine Analogs and their use as Immunomodulating Agents." The patent relates to ISA247, its next-generation calcineurin inhibitor in Phase II development as immunosuppressive therapy in organ transplantation and in the treatment of autoimmune diseases.
Targeted Genetics Corp., of Seattle, was issued U.S. Patent No. 6,596,535 titled "Metabolically Activated Recombinant Viral Vectors and Methods for Their Preparation and Use," an additional patent related to its adeno-associated virus (AAV) vector construct.